METHYLOMIC_EU

The third issue of the METHYLOMIC Project Newsletter was released! We are excited to share updates on our progress with all our stakeholders. This newsletter is released quarterly, aiming to keep everyone informed about the significant developments and achievements within our consortium. Read the newsletter: https://lnkd.in/eQVNam7Z

📢 We are hiring! EFCCA is looking for a Project Assistant. If you're passionate about supporting meaningful projects in the IBD community, this might be your opportunity! 🌍 Apply here: https://lnkd.in/dCH4u75b #JoinOurTeam #ProjectAssistant

This online workshop will bring together patients, researchers and clinicians to foster mutual understanding of the challenges, expectations and perspectives on the use of Artificial Intelligence (AI) and IBD care. Throughout the session, the different stakeholders will explain how AI technologies are applied in research and IBD care, and the extraordinary impact they can have on the management of IBD. The workshop will feature a Q&A session, and a panel discussion designed to encourage dialogue and active participation from attendees. EFCCA aims at reaching consensus on a joint Call to Action on AI and IBD care. ➡️ 21 October 2024 ➡️17:00 to 19:00 CET ➡️Hosted by European Federation of Crohn's and Ulcerative Colitis Associations More information and how to register: https://lnkd.in/e-TpsQJU

In the fourth episode of METHYLOMIC matters our attention centers on a crucial element of METHYLOMIC: the development of an easy-to-use diagnostic test intended for clinical validation, with the ultimate aim of global adoption in medical centers. With Dr. Peter Henneman and Dr. Jules Petit we discuss the importance of a rapid assay and compare its pros and cons opposed to the current EPIC array methodology. All this and more in the fourth episode of METHYLOMIC matters! You can listen to the METHYLOMIC podcast through Spotify, Podimo, Apple, Pca.st: https://lnkd.in/efj_KTbH #METHYLOMIC #Podcast #epigenetics #HorizonEU

In the third episode of METHYLOMIC matters we delve into the intricate machine learning methodology behind the successful prediction models developed by HORAIZON’s founder and CEO, dr. Evgeni Levin, PhD. We explore essential elements of the methodology, comparing linear and non-linear models, emphasizing the significance of multivariate models, and addressing strategies for mitigating overfitting. Furthermore, we delve into the prospective clinical applications of these models and their ultimate integration into clinical practice. All this and more in the third episode of METHYLOMIC matters! Listen to the podcast: https://lnkd.in/eUHtj7Nv #METHYLOMIC #machinelearning #epigenetics

The second issue of the METHYLOMIC Project Newsletter is online! We are excited to share updates on our progress with all our stakeholders. This newsletter is released quarterly, aiming to keep everyone informed about the significant developments and achievements within our consortium. We hope you enjoy this edition and have a wonderful summer break: https://lnkd.in/e_Xk-9wn #METHYLOMIC #epigenetics #Crohn

Three questions for Sarah van Zon, PhD candidate clinical research, Amsterdam UMC: ❓ What makes this study unique compared to other research being conducted on Crohn’s disease? 💁♀️ “This study is unique because it focuses on the predictive power of DNA methylation patterns for therapy response. While most Crohn’s disease researches emphasize genetic mutations or inflammatory biomarkers, this study investigates the role of epigenetic biomarkers, leading to a new perspective on therapy response prediction. In addition, this research emphasizes the importance of epigenetic modifications in the pathophysiology of complex diseases such as Crohn’s disease and Psoriasis, leading to advancements in precision medicine.” Read more: https://lnkd.in/eDGs9Gmq #METHYLOMIC #epigenetics #crohn #colitis #psoriasis

Methylomic Matters is a podcastseries by the METHYLOMIC project: a program committed to bringing personalised treatment-selection in Crohn’s disease and other immune-mediated inflammatory diseases to clinical practice. In this second episode of METHYLOMIC matters we have the privilege of conversing with Professor Geert D’Haens and Dr. Andrew Li Yim as we delve into the pre-METHYLOMIC era and discover the science behind the OMICROHN trial: the EPIC-CD study. How did we design this biomarker discovery study and what are key important methodological steps? What were the main results and how do we envision the future? On our website you will find links to the different podcast channels: https://lnkd.in/g-p23zfT #METHYLOMIC #epigenetics #biomarker #crohns #OMICROHN

Today is World IBD Day. An important day for IBD patients to bring attention to the effects of their disease. Many people with IBD experience long-term symptoms such as severe fatigue and abdominal pain. With the METHYLOMIC project we want to improve the treatment of people with Crohn's disease. METHYLOMIC is committed to bringing personalised treatment-selection in Crohn’s disease and other immune-mediated inflammatory diseases to clinical practice. Read more about our project: https://lnkd.in/gMSiMKbh #WorldIBDday #worldIBDday2024 #METHYLOMIC #IBDhasnoborders #Crohns

Also check out this position! Andrew Li Yim https://lnkd.in/ebqeF7Cs